Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 49

1.

Increased Accumulation and Retention of rhFVIIa (eptacog beta) in Knee Joints of Hemophilia A Mice Compared to Wild-Type Mice.

Magisetty J, Pendurthi UR, Madhunapantula SV, Grandoni J, Rao LVM.

Thromb Haemost. 2019 Aug;119(8):1283-1294. doi: 10.1055/s-0039-1688907. Epub 2019 May 26.

PMID:
31129915
2.

Treatment With Naringenin Elevates the Activity of Transcription Factor Nrf2 to Protect Pancreatic β-Cells From Streptozotocin-Induced Diabetes in vitro and in vivo.

Rajappa R, Sireesh D, Salai MB, Ramkumar KM, Sarvajayakesavulu S, Madhunapantula SV.

Front Pharmacol. 2019 Jan 28;9:1562. doi: 10.3389/fphar.2018.01562. eCollection 2018.

3.

Tricaproin Isolated From Simarouba glauca Inhibits the Growth of Human Colorectal Carcinoma Cell Lines by Targeting Class-1 Histone Deacetylases.

Jose A, Chaitanya MVNL, Kannan E, Madhunapantula SV.

Front Pharmacol. 2018 Mar 12;9:127. doi: 10.3389/fphar.2018.00127. eCollection 2018.

4.

Unmethylated promoter DNA correlates with p53 expression and apoptotic levels only in Vitamin B9 and B12 deficient megaloblastic anemia but not in non-megaloblastic anemia controls.

Yadav MK, Manoli NM, Vimalraj S, Madhunapantula SV.

Int J Biol Macromol. 2018 Apr 1;109:76-84. doi: 10.1016/j.ijbiomac.2017.12.070. Epub 2017 Dec 13.

PMID:
29246873
5.

Induction of colon and cervical cancer cell death by cinnamic acid derivatives is mediated through the inhibition of Histone Deacetylases (HDAC).

Anantharaju PG, Reddy DB, Padukudru MA, Chitturi CMK, Vimalambike MG, Madhunapantula SV.

PLoS One. 2017 Nov 30;12(11):e0186208. doi: 10.1371/journal.pone.0186208. eCollection 2017.

6.

Identification of WEE1 as a target to make AKT inhibition more effective in melanoma.

Kuzu OF, Gowda R, Sharma A, Noory MA, Kardos G, Madhunapantula SV, Drabick JJ, Robertson GP.

Cancer Biol Ther. 2018 Jan 2;19(1):53-62. doi: 10.1080/15384047.2017.1360446. Epub 2017 Nov 30.

7.

Linoleic acid metabolite leads to steroid resistant asthma features partially through NF-κB.

Panda L, Gheware A, Rehman R, Yadav MK, Jayaraj BS, Madhunapantula SV, Mahesh PA, Ghosh B, Agrawal A, Mabalirajan U.

Sci Rep. 2017 Aug 29;7(1):9565. doi: 10.1038/s41598-017-09869-9.

8.

Naturally occurring benzoic acid derivatives retard cancer cell growth by inhibiting histone deacetylases (HDAC).

Anantharaju PG, Reddy BD, Padukudru MA, Kumari Chitturi CM, Vimalambike MG, Madhunapantula SV.

Cancer Biol Ther. 2017 Jul 3;18(7):492-504. doi: 10.1080/15384047.2017.1324374. Epub 2017 May 16.

9.

Targeting protein kinase-b3 (akt3) signaling in melanoma.

Madhunapantula SV, Robertson GP.

Expert Opin Ther Targets. 2017 Mar;21(3):273-290. doi: 10.1080/14728222.2017.1279147. Epub 2017 Jan 16. Review.

PMID:
28064546
10.

An overview on the role of dietary phenolics for the treatment of cancers.

Anantharaju PG, Gowda PC, Vimalambike MG, Madhunapantula SV.

Nutr J. 2016 Dec 1;15(1):99. Review.

11.

Evaluation of inflammatory markers interleukin-6 (IL-6) and matrix metalloproteinase-9 (MMP-9) in asthma.

Naik SP, P A M, B S J, Madhunapantula SV, Jahromi SR, Yadav MK.

J Asthma. 2017 Aug;54(6):584-593. doi: 10.1080/02770903.2016.1244828. Epub 2016 Oct 26.

PMID:
27780376
12.

Comparative Assessment of Vitamin-B12, Folic Acid and Homocysteine Levels in Relation to p53 Expression in Megaloblastic Anemia.

Yadav MK, Manoli NM, Madhunapantula SV.

PLoS One. 2016 Oct 25;11(10):e0164559. doi: 10.1371/journal.pone.0164559. eCollection 2016.

13.

Application of quality-by-design approach to optimize diallyl disulfide-loaded solid lipid nanoparticles.

Talluri SV, Kuppusamy G, Karri VV, Yamjala K, Wadhwani A, Madhunapantula SV, Pindiprolu SS.

Artif Cells Nanomed Biotechnol. 2017 May;45(3):474-488. doi: 10.3109/21691401.2016.1173046. Epub 2016 Apr 25.

PMID:
27112220
14.

Lipid-based nanocarriers for breast cancer treatment - comprehensive review.

Talluri SV, Kuppusamy G, Karri VV, Tummala S, Madhunapantula SV.

Drug Deliv. 2016 May;23(4):1291-305. doi: 10.3109/10717544.2015.1092183. Epub 2015 Oct 2.

PMID:
26430913
15.
16.

Mucosal vaccines: a paradigm shift in the development of mucosal adjuvants and delivery vehicles.

Srivastava A, Gowda DV, Madhunapantula SV, Shinde CG, Iyer M.

APMIS. 2015 Apr;123(4):275-88. doi: 10.1111/apm.12351. Epub 2015 Jan 29. Review.

PMID:
25630573
17.

Nanolipolee-007, a novel nanoparticle-based drug containing leelamine for the treatment of melanoma.

Gowda R, Madhunapantula SV, Sharma A, Kuzu OF, Robertson GP.

Mol Cancer Ther. 2014 Oct;13(10):2328-40. doi: 10.1158/1535-7163.MCT-14-0357. Epub 2014 Jul 31.

18.

Design and development of oral nanoparticulated insulin in multiple emulsion.

Siddhartha TV, Senthil V, Kishan IS, Khatwal RB, Madhunapantula SV.

Curr Drug Deliv. 2014;11(4):472-85.

PMID:
24730439
19.

Targeting multiple key signaling pathways in melanoma using leelamine.

Gowda R, Madhunapantula SV, Kuzu OF, Sharma A, Robertson GP.

Mol Cancer Ther. 2014 Jul;13(7):1679-89. doi: 10.1158/1535-7163.MCT-13-0867. Epub 2014 Mar 31.

20.

Dipeptidyl peptidase-4 inhibition by Pterocarpus marsupium and Eugenia jambolana ameliorates streptozotocin induced Alzheimer's disease.

Kosaraju J, Madhunapantula SV, Chinni S, Khatwal RB, Dubala A, Muthureddy Nataraj SK, Basavan D.

Behav Brain Res. 2014 Jul 1;267:55-65. doi: 10.1016/j.bbr.2014.03.026. Epub 2014 Mar 22.

PMID:
24667360
21.

Identification of glycogen synthase kinase 3α as a therapeutic target in melanoma.

Madhunapantula SV, Sharma A, Gowda R, Robertson GP.

Pigment Cell Melanoma Res. 2013 Nov;26(6):886-99. doi: 10.1111/pcmr.12156. Epub 2013 Sep 19.

22.

Identification of aurora kinase B and Wee1-like protein kinase as downstream targets of (V600E)B-RAF in melanoma.

Sharma A, Madhunapantula SV, Gowda R, Berg A, Neves RI, Robertson GP.

Am J Pathol. 2013 Apr;182(4):1151-62. doi: 10.1016/j.ajpath.2012.12.019. Epub 2013 Feb 12.

23.

Current and future trials of targeted therapies in cutaneous melanoma.

Evans MS, Madhunapantula SV, Robertson GP, Drabick JJ.

Adv Exp Med Biol. 2013;779:223-55. doi: 10.1007/978-1-4614-6176-0_10. Review.

24.

Simultaneous targeting of COX-2 and AKT using selenocoxib-1-GSH to inhibit melanoma.

Gowda R, Madhunapantula SV, Desai D, Amin S, Robertson GP.

Mol Cancer Ther. 2013 Jan;12(1):3-15. doi: 10.1158/1535-7163.MCT-12-0492. Epub 2012 Oct 30.

25.

Chemoprevention of melanoma.

Madhunapantula SV, Robertson GP.

Adv Pharmacol. 2012;65:361-98. doi: 10.1016/B978-0-12-397927-8.00012-9. Review.

26.

Selenium-containing histone deacetylase inhibitors for melanoma management.

Gowda R, Madhunapantula SV, Desai D, Amin S, Robertson GP.

Cancer Biol Ther. 2012 Jul;13(9):756-65. Epub 2012 Jun 6.

27.

Targeting sphingosine kinase-1 to inhibit melanoma.

Madhunapantula SV, Hengst J, Gowda R, Fox TE, Yun JK, Robertson GP.

Pigment Cell Melanoma Res. 2012 Mar;25(2):259-74. doi: 10.1111/j.1755-148X.2012.00970.x.

28.

The Akt signaling pathway: an emerging therapeutic target in malignant melanoma.

Madhunapantula SV, Mosca PJ, Robertson GP.

Cancer Biol Ther. 2011 Dec 15;12(12):1032-49. doi: 10.4161/cbt.12.12.18442. Epub 2011 Dec 15. Review.

29.

Toxicological considerations when creating nanoparticle-based drugs and drug delivery systems.

Sharma A, Madhunapantula SV, Robertson GP.

Expert Opin Drug Metab Toxicol. 2012 Jan;8(1):47-69. doi: 10.1517/17425255.2012.637916. Epub 2011 Nov 19. Review.

30.

Therapeutic Implications of Targeting AKT Signaling in Melanoma.

Madhunapantula SV, Robertson GP.

Enzyme Res. 2011 Mar 23;2011:327923. doi: 10.4061/2011/327923.

31.

Melanoma prevention using topical PBISe.

Chung CY, Madhunapantula SV, Desai D, Amin S, Robertson GP.

Cancer Prev Res (Phila). 2011 Jun;4(6):935-48. doi: 10.1158/1940-6207.CAPR-10-0202. Epub 2011 Mar 2.

32.

In situ photoimmunotherapy: a new hope for cutaneous melanoma patients.

Madhunapantula SV, Gowda R, Inamdar GS, Robertson GP.

Cancer Biol Ther. 2010 Dec 1;10(11):1088-90. Epub 2010 Dec 1. No abstract available.

PMID:
21178399
33.

Steroid hormones drive cancer development.

Madhunapantula SV, Mosca P, Robertson GP.

Cancer Biol Ther. 2010 Oct 15;10(8):765-6. Epub 2010 Oct 15. No abstract available.

PMID:
20935464
34.

Targeting the MAPK pathway in melanoma: why some approaches succeed and other fail.

Inamdar GS, Madhunapantula SV, Robertson GP.

Biochem Pharmacol. 2010 Sep 1;80(5):624-37. doi: 10.1016/j.bcp.2010.04.029. Epub 2010 May 9. Review.

35.

Synthesis and characterization of a novel iNOS/Akt inhibitor Se,Se'-1,4-phenylenebis(1,2-ethanediyl)bisisoselenourea (PBISe)--against colon cancer.

Desai D, Madhunapantula SV, Gowdahalli K, Sharma A, Chandagaludoreswamy R, El-Bayoumy K, Robertson GP, Amin S.

Bioorg Med Chem Lett. 2010 Mar 15;20(6):2038-43. doi: 10.1016/j.bmcl.2009.09.071. Epub 2009 Sep 22.

36.

The PTEN-AKT3 signaling cascade as a therapeutic target in melanoma.

Madhunapantula SV, Robertson GP.

Pigment Cell Melanoma Res. 2009 Aug;22(4):400-19. doi: 10.1111/j.1755-148X.2009.00585.x. Epub 2009 May 28. Review.

37.

Targeting Akt3 signaling in malignant melanoma using isoselenocyanates.

Sharma A, Sharma AK, Madhunapantula SV, Desai D, Huh SJ, Mosca P, Amin S, Robertson GP.

Clin Cancer Res. 2009 Mar 1;15(5):1674-85. doi: 10.1158/1078-0432.CCR-08-2214. Epub 2009 Feb 10.

38.

Synthesis and anticancer activity comparison of phenylalkyl isoselenocyanates with corresponding naturally occurring and synthetic isothiocyanates.

Sharma AK, Sharma A, Desai D, Madhunapantula SV, Huh SJ, Robertson GP, Amin S.

J Med Chem. 2008 Dec 25;51(24):7820-6. doi: 10.1021/jm800993r.

39.

Structural interactions in chondroitin 4-sulfate mediated adherence of Plasmodium falciparum infected erythrocytes in human placenta during pregnancy-associated malaria.

Achur RN, Kakizaki I, Goel S, Kojima K, Madhunapantula SV, Goyal A, Ohta M, Kumar S, Takagaki K, Gowda DC.

Biochemistry. 2008 Nov 25;47(47):12635-43. doi: 10.1021/bi801643m.

40.

PBISe, a novel selenium-containing drug for the treatment of malignant melanoma.

Madhunapantula SV, Desai D, Sharma A, Huh SJ, Amin S, Robertson GP.

Mol Cancer Ther. 2008 May;7(5):1297-308. doi: 10.1158/1535-7163.MCT-07-2267.

41.

Akt3 and mutant V600E B-Raf cooperate to promote early melanoma development.

Cheung M, Sharma A, Madhunapantula SV, Robertson GP.

Cancer Res. 2008 May 1;68(9):3429-39. doi: 10.1158/0008-5472.CAN-07-5867.

42.

Binding affinity of Plasmodium falciparum-infected erythrocytes from infected placentas and laboratory selected strains to chondroitin 4-sulfate.

Achur RN, Muthusamy A, Madhunapantula SV, Gowda DC.

Mol Biochem Parasitol. 2008 May;159(1):79-84. doi: 10.1016/j.molbiopara.2008.02.002. Epub 2008 Feb 14.

43.

Is B-Raf a good therapeutic target for melanoma and other malignancies?

Madhunapantula SV, Robertson GP.

Cancer Res. 2008 Jan 1;68(1):5-8. doi: 10.1158/0008-5472.CAN-07-2038. Review.

45.

The effect of substitution of the N-acetyl groups of N-acetylgalactosamine residues in chondroitin sulfate on its degradation by chondroitinase ABC.

Madhunapantula SV, Achur RN, Bhavanandan VP, Gowda DC.

Glycoconj J. 2007 Nov;24(8):465-73. Epub 2007 May 29.

PMID:
17533514
46.

PRAS40 deregulates apoptosis in malignant melanoma.

Madhunapantula SV, Sharma A, Robertson GP.

Cancer Res. 2007 Apr 15;67(8):3626-36.

47.
48.

Chondroitin sulfate proteoglycans of bovine cornea: structural characterization and assessment for the adherence of Plasmodium falciparum-infected erythrocytes.

Achur RN, Muthusamy A, Madhunapantula SV, Bhavanandan VP, Seudieu C, Channe Gowda D.

Biochim Biophys Acta. 2004 Sep 1;1701(1-2):109-19.

PMID:
15450180
49.

Structural characterization of the bovine tracheal chondroitin sulfate chains and binding of Plasmodium falciparum-infected erythrocytes.

Muthusamy A, Achur RN, Valiyaveettil M, Madhunapantula SV, Kakizaki I, Bhavanandan VP, Gowda CD.

Glycobiology. 2004 Jul;14(7):635-45. Epub 2004 Mar 24.

PMID:
15044390

Supplemental Content

Loading ...
Support Center